Worldwide, more than 1 million sexually transmitted infections (STIs) are acquired every single day, according to the WHO.
Chlamydia (CT) and gonorrhea (NG) are incredibly prevalent sexually transmitted diseases that can bare risk to the individual but that also pose an important public health problem.
Late diagnosis and treatment
Untreated infections can have important consequences for both men and women. These infections should be treated with the proper recommended antibiotics, to prevent further increase in antimicrobial resistance.
Continuous spread of these diseases is facilitated by asymptomatic transmission, making the management of these infections a difficult task to undertake.
Early diagnosis and adequate treatment administration is therefore crucial for individual patients and public health.
The Rapidemic technology provides doctors with actionable information to treat patients. Fast results facilitate on-the-spot testing, giving healthcare practitioners the information they need to prescribe the right treatment, thereby preventing further resistance.
The Rapidemic test also supports public health efforts to mediate the spread of STI’s in communities. The test allows decentralized testing of chlamydia and gonorrhea with an accuracy similar to that of PCR tests. Thereby bringing diagnostics closer to patients in high-risk groups, lowering the threshold to test, and annihilating further spread of the infections in the community.
Rapidemic provides a single-visit outcome for immediate and tailored treatment administration.
The Rapidemic test combines the accuracy of molecular diagnostics with the ease-of-use of decentralized tests.
The test is ease-to-use, compact and portable and can be performed by minimally trained personnel.
How? Learn more about Rapidemic’s technology